Abstract:<p>Chemotherapeutic strategy has been widely used for treating malignance by targeting irregular expressed or mutant proteins with small molecular inhibitors (SMIs) or monoclonal antibodies (mAbs). However, most intracellular proteins lack of active sites or antigens where SMIs or mAbs bind with, and are called as non-druggable targets for a long time. From the first year of this century, PROteolysis-TArgeting Chimeras (PROTACs) has emerged to be a promising approach for proteins, including those non-druggable ones, such as transcriptional factors and scaffold proteins. The first generation of peptide-based PROTACs adopts β-TrCP and VHL as E3 ligases, but the cellular permeability and chemical stability issues restrict their clinical application. The second generation of small molecule-based PROTACs adopts MDM2, VHL, IAPs and Cereblon as E3 ligases have been tensely studied. To date, the targets of PROTACs including those overexpressed oncogenic proteins such as ER, AR and BRDs, disease-relevant fusion proteins such as NPM/EML4-ALK and BCL-ABL, cancer-driven mutant proteins such as EGFR, kinases such as CDKs and RTKs. The major disadvantage of PROTACs is the noncancer specificity and relative higher toxicity, due to its catalytic role. To overcome this, we and other have recently developed several similar light-controllable PROTACs, termed as the third generation controllable PROTACs. The degradation of targets by those PROTACs can be triggered by UVA or visible light, providing a tool box for further PROTACs design. Here in this review, we introduce the historical milestones and prospective for further PROTACs development in clinical use.</p>

Telomerase Reverse Transcriptase Degradation via a Rationally Designed Covalent Proteolysis Targeting Chimera

Telomere Targeting Chimera Enables Targeted Destruction of Telomeric Repeat-Binding Factor Proteins.

Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future

Addressing the Enzyme-independent tumor-promoting function of NAMPT via PROTAC-mediated degradation

ClickRNA-PROTAC for Tumor-Selective Protein Degradation and Targeted Cancer Therapy

Radiotherapy-Triggered Proteolysis Targeting Chimera Prodrug Activation in Tumors

Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy

Tumor-targeted PROTAC prodrug nanoplatform enables precise protein degradation and combination cancer therapy

PROTACs: Current and Future Potential as a Precision Medicine Strategy to Combat Cancer

DNA-templated spatially controlled proteolysis targeting chimeras for CyclinD1-CDK4/6 complex protein degradation

Protein Degradation by In-Cell Self-Assembly of Proteolysis Targeting Chimeras

A region-confined PROTAC nanoplatform for spatiotemporally tunable protein degradation and enhanced cancer therapy

Advancing Proteolysis Targeting Chimera (PROTAC) Nanotechnology in Protein Homeostasis Reprograming for Disease Treatment

A modular PROTAC design for target destruction using a degradation signal based on a single amino acid

Hydrogen Peroxide-Inducible PROTACs for Targeted Protein Degradation in Cancer Cells

Restraining the power of Proteolysis Targeting Chimeras in the cage: A necessary and important refinement for therapeutic safety

PROTACs: A novel strategy for cancer therapy

PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy

Iterative Design and Optimization of Initially Inactive Proteolysis Targeting Chimeras (PROTACs) Identify VZ185 as a Potent, Fast, and Selective von Hippel–Lindau (VHL) Based Dual Degrader Probe of BRD9 and BRD7

Recent Advances in Pro-PROTAC Development to Address On-Target Off-Tumor Toxicity.

Proteolysis-targeting chimeras (PROTACs) in cancer therapy